Breakthrough methods of treatment and diagnostics in the field of children's oncology, hematology and immunology

Every year, 300—350 new cases of malignant neoplasms are detected in the pediatric population of Belarus. All children, and in case of some oncohematological diseases, young adults under 30, receive treatment at the Republican Scientific and Practical Center for Children's Oncology, Hematology and Immunology (Belarus), where the most advanced technologies and methods are developed and implemented. This allows achieving results at the level of the world's leading pediatric oncology centers: the 5-year survival rate for the last year was 83 %, for certain nosologies — exceeds 90 %. Today, pediatric oncology needs to focus on the problem of finding ways to individualize treatment to reduce the number of relapses without losing the achieved high efficiency. Immunotherapy, biotechnology and molecular genetic research are innovative areas in the field of oncological care for children. These approaches are not only focused on social needs, but are also economically justified, contribute to improving the results of diagnosis and treatment, improving the quality of life of patients and reducing the degree of disability. This article is devoted to the key innovative developments of the Republican Scientific and Practical Center for Children's Oncology, Hematology and Immunology, introduced over the past two years into practical healthcare in Belarus, such as CAR-T therapy, immunotherapy using human natural killer cells and high-throughput sequencing, which demonstrate high efficiency and promise broad prospects for future use not only in pediatric oncology. The article presents the main results of clinical trials and further opportunities for technology development.